Vignesh Packiam, MD, discusses optimizing BCG treatment in high-risk NMIBC, including patient selection for combination immunotherapy and treatment-related trade-offs.
News|Articles|July 3, 2025
FDA news recap in urology for Q2 2025
Fact checked by: Patrick Campbell
Here’s a look back at notable news between April and June 2025.
Advertisement
Advertisement
The specialty of urology, following an eventful first quarter, had a busy Q2 with a flurry of FDA approvals (and 1 notable non-approval) ranging from benign prostatic hyperplasia (BPH) to urge incontinence to bladder cancer and prostate cancer.
Related to this article
A national survey of US military service members and veterans with NMIBC found that more than half were diagnosed by age 50, while 63% reported treatment access barriers.
VOLGA results raise the question of treatment de-intensification in perioperative MIBC care, according to Suzanne B. Merrill, MD, FACS.
Virtuoso Surgical expects to initiate a focused US launch at leading urology centers in 2027.
Pasritamig is being evaluated with or without JNJ-9401 in the ongoing phase 3 KLK2-comPAS trial.
The combination of nogapendekin alfa inbakicept plus BCG demonstrated a statistically significant improvement in efficacy vs BCG alone.
These FAQs outline key recommendations from ASTRO's updated guideline on shorter-course radiation therapy for localized prostate cancer.
Patient goals, disease features, and response to prior therapy guide treatment choices across high-risk NMIBC, according to Suzanne B. Merrill, MD, FACS.
Advertisement
Advertisement